Texas Attorney General Ken Paxton sued Eli Lilly (LLY) for “bribing and illegally inducing medical providers to prescribe its most profitable drugs,” including the high-demand GLP-1 medications Mounjaro and Zepbound that are used for weight loss and diabetes treatment, the AG announced. “Big Pharma compromised medical decision-making by engaging in an illegal kickback scheme. Eli Lilly fraudulently sought to maximize profits at taxpayer expense and put corporate greed over people’s health. I will not stand by while corporations unlawfully manipulate our healthcare system to line their own pockets,” said Attorney General Paxton.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Eli Lilly’s Orforglipron Study: A Potential Game-Changer in Obesity Treatment
- Eli Lilly’s Orforglipron Study: A New Hope for Obesity Treatment?
- VOO ETF News, 8/12/2025
- Analysts Reaffirm Buy Ratings on Eli Lilly After Stock Suffers Worst Decline Since 2008
- UnitedHealth Stock (UNH) Tumbles 50% YTD; Here’s How to Buy the Dip Without the Risk